TITLE

Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs

AUTHOR(S)
Inadomi, John M.; McIntyre, Lisa; Bernard, Latoya; Fendrick, A. Mark
PUB. DATE
September 2003
SOURCE
American Journal of Gastroenterology;Sep2003, Vol. 98 Issue 9, p1940
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
: ObjectivesManagement costs for gastroesophageal reflux disease are high because of the expensive medications used for maintenance therapy. Previous studies have illustrated the success of step-down from proton pump inhibitors (PPIs) to less-expensive therapy once symptoms have abated. This study was conducted to determine whether patients requiring greater than single-dose PPI for initial symptom resolution could be stepped-down to single-dose PPI and whether this intervention decreased costs or adversely affected quality of life.: MethodsConsecutive patients in whom greater than single-dose PPI had completely alleviated reflux-type symptoms (heartburn or acid regurgitation) were recruited through the use of pharmacy records of PPI prescriptions. Eligible subjects completed baseline demographic information and quality-of-life surveys and were stepped-down to single-dose PPI (lansoprazole 30 mg or omeprazole 20 mg daily). Follow-up continued for 6 months or until subjects reported recurrence of reflux-type symptoms, at which point PPIs were reinstituted at the dose that had originally alleviated the subjects'' symptoms. The primary outcome was the proportion of subjects in whom step-down was successful, defined as no recurrence of reflux-type symptoms on single-dose PPI.: ResultsA total of 117 subjects enrolled in the study; all were followed to the primary endpoint. 79.5% did not report recurrent symptoms of heartburn or acid regurgitation during the 6 months after step-down to single-dose PPI. Logistic regression revealed that longer duration of PPI use before study enrollment was associated with greater likelihood of symptom recurrence with step-down. Although quality of life was not significantly altered, dyspepsia (excluding reflux-type symptoms) increased. Overall costs of management were reduced.: ConclusionsThe majority of patients rendered asymptomatic on greater than single-dose PPI might be subsequently stepped-down to single-dose therapy without recurrence of reflux-type symptoms. This intervention can decrease management costs without adversely affecting quality of life.
ACCESSION #
10807791

 

Related Articles

  • Withdrawing PPI Therapy: Response to Metz et al. Waldum, Helge L; Sandvik, Arne K; Hauso, Øyvind; Qvigstad, Gunnar; Fossmark, Reidar // American Journal of Gastroenterology;Feb2012, Vol. 107 Issue 2, p325 

    A letter to the editor is presented in response to the article by D. C. Metz and colleagues on proton pump inhibitors (PPI) therapy withdrawal after healing esophagitis in the 2011 issue.

  • Effect of Up to 3 Years of High-dose Lansoprazole on Barrett's Esophagus. Sampliner, R. E. // American Journal of Gastroenterology;Oct1994, Vol. 89 Issue 10, p1844 

    Objective: Barrett's esophagus is a metaplastic condition resulting from gastroesophageal reflux disease. Previous medical and surgical therapies have failed to predictably eradicate Barrett's. The objective of this study was to assess the impact of long-term, high-dose lansoprazole, a proton...

  • Prospective Study Examining the Impact of Multichannel Intraluminal Impedance on Antireflux Surgery. Gruebel, C.; Linke, G.; Tutuian, R.; Hebbard, G.; Zerz, A.; Meyenberger, C.; Borovicka, J. // Surgical Endoscopy;May2008, Vol. 22 Issue 5, p1241 

    Reflux monitoring using combined multichannel intraluminal impedance (MII) and pH-metry increases the sensitivity for identifying gastroesophageal reflux episodes. The likelihood of a positive symptom index (SI) for patients with reflux disease (gastroesophageal reflux disease [GERD] or...

  • Proton Pump Inhibitors or Histamine-2 Receptor Antagonists for the Prevention of Recurrences of Erosive Reflux Esophagitis: A Cost-Effectiveness Analysis. Harris, Ryan A.; Kuppermann, Miriam; Richter, Joel E. // American Journal of Gastroenterology;Dec1997, Vol. 92 Issue 12, p2179 

    Objectives: Erosive esophagitis is a recurring condition for which many patients require preventive therapy. If maintenance therapy must be provided, the most cost-effective treatment strategy should be established. We evaluated the and benefits associated with three treatment strategies: 1)...

  • Reflux Monitoring: On or Off Therapy? Vaezi, Michael F. // American Journal of Gastroenterology;Feb2011, Vol. 106 Issue 2, p183 

    The role of esophageal pH (or impedance) monitoring in diagnosing gastroesophageal reflux disease (GERD) has evolved over the years. In the era of empiric therapy with potent acid-suppressive agents such as proton pump inhibitors (PPIs), esophageal reflux monitoring is often reserved for...

  • Gastroesophageal Reflux in Children: Pathogenesis, Prevalence, Diagnosis, and Role of Proton Pump Inhibitors in Treatment. Gold, B.D.; Freston, J.W. // Pediatric Drugs;2002, Vol. 4 Issue 10, p673 

    A substantial percentage of infants, children and adolescents experience gastroesophageal reflux disease (GERD) and its accompanying symptoms, as well as disease complications. The diagnosis of GERD in children is made based upon the child's history, and data derived primarily from pH monitoring...

  • Barrett's Esophagus: Symptoms, Diagnosis, and Treatment. Green, Erin E. // Clinical Excellence for Nurse Practitioners;Spring2005, Vol. 9 Issue 1, p7 

    Patients experiencing gastroesophageal reflux on a regular basis may be predisposed to Barrett's esophagus. Barrett's is thought to be a precursor to esophageal cancer. Endoscopy is utilized for both diagnosis and surveillance of this disease. The use of proton pump inhibitors and H2 blockers...

  • I've had heartburn problems. A recent endoscopy showed some inflammation in my esophagus. Now I'm taking a medication for it. How long will I have to take it?  // Mayo Clinic Health Letter;May2011, Vol. 29 Issue 5, p8 

    The article presents questions and answers related to dealing with medication for heartburn.

  • Which drug class is best for GERD? DiLoreto, Stacy; Hsu, Ronald; Wolfgang, Robert // Patient Care;9/15/2000, Vol. 34 Issue 17, p26 

    Determines which drug class is most suitable for treating gastroesophageal reflux disease (GERD). Percentage of Americans affected by GERD; Effectiveness of H(sub 2) receptor antagonists, promotility agents and proton pump inhibitors; Three approaches used to treat GERD; Recommendation for...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics